May 29th 2025, 9:00pm
Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer.
May 29th 2025, 8:00pm
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
May 29th 2025, 7:00pm
Christine Simonelli, B.S.N., RN, CCRC, OCN, is amazing, and goes out of her way to help patients and providers.
May 29th 2025, 5:00pm
I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease myself.
May 29th 2025, 4:16pm
The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in the U.S. has been withdrawn.
May 29th 2025, 3:00pm
The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer.
May 29th 2025, 1:00pm
Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining treatment with PARP inhibitors.
May 28th 2025, 8:00pm
Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.
May 28th 2025, 7:00pm
Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias.
May 28th 2025, 5:00pm
After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways to stay strong and resilient.
Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment
Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis
Guiding Light: A Journey of Support and Hope
Tracing a Five-Generation Cancer Legacy Through Genetic Discovery